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Abstract
Background: Prior studies suggest soluble fibers may favorably affect glucose/insulin metabolism.
Methods: This prospective, randomized, placebo controlled, double blind, parallel group trial evaluated 50
generally healthy subjects without prior diagnosis of diabetes mellitus (44 completers), who were administered
beverages containing placebo (control), lower dose (3 g/d), or higher dose (6 g/d) reduced viscosity barley b-
glucan (BBG) extract. Subjects (68% women) mean age 56 years, Body Mass Index (BMI) 32 kg/m2 and baseline
fasting plasma glucose 102 mg/dl were instructed to follow a weight-maintaining Therapeutic Lifestyle Changes
(TLC) diet and consumed three 11 oz study beverages daily with meals for 12 weeks. The four primary study
endpoint measures were plasma glucose and insulin [each fasting and post-Oral Glucose Tolerance Testing (OGTT)].
Results: Compared to placebo, administration of 3 g/d BBG over 12 weeks significantly reduced glucose
incremental Area Under the Curve (iAUC) measures during OGTT and 6 g/d BBG over 12 weeks significantly
reduced fasting insulin as well as the related homeostasis model assessment of insulin resistance (HOMA-IR).
Beverages were generally well tolerated with no serious adverse experiences and no significant differences
between groups for adverse experiences. Per protocol instruction, subjects maintained body weight.
Conclusions: These findings suggest 6 g/d BBG consumed in a beverage over 12 weeks may improve insulin
sensitivity among hyperglycemic individuals with no prior diagnosis of diabetes mellitus, and who experience no
change in body weight.
Trial Registration: ClinicalTrials.gov Identifier: NCT01375803.
Keywords: insulin sensitivity, insulinemia, glycemia, barley beta glucan, randomized controlled trial
Introduction
Type 2 diabetes mellitus (T2DM) is increasing as a
worldwide, major health epidemic [1,2]. Individuals at
increased risk for developing T2DM include those who
are 45 years old or greater, have a family history of
T2DM, lead a sedentary lifestyle, or have high blood
pressure. When combined with other risk factors such
as serum triglycerides greater than 150 mg/dl or a body
mass index (BMI) greater than 30 kg/m2, fasting plasma
glucose between 91-99 mg/dl may increase the risk of
T2DM [3,4]. One of the potential opportunities in asses-
sing early hyperglycemia is that those with recent onset,
mild hyperglycemia may be especially responsive to
nutritional and lifestyle interventions, with greater
improvements in fasting glucose levels [5] and slowed
progression towards development of T2DM [6].
Data suggest whole grain consumption or cereal fiber
intake may reduce glucose levels, and reduce the risk
for developing T2DM [7,8]. A meta-analysis of 13 pro-
spective cohort studies including 427,935 individuals
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indicated individuals in the highest quintile for whole
grain or cereal fiber intake had a 29% lower risk for
developing T2DM than those in the lowest quintile [9].
Viscous soluble fiber intake has favorable effects on
postprandial glycemia and insulinemia with improved
insulin sensitivity, suggesting a potential mechanism for
reduced risk for developing T2DM [10-15]. Several prior
reports [16-20] suggest BBG, a soluble fiber, may lower
postprandial glucose and insulin; however, most of these
were single meal test studies of limited duration (i.e.
one test meal time point for food consumption).
The purpose of this 12-week study was to evaluate a
flavored water beverage containing reduced viscosity
BBG on glucose metabolism and insulin sensitivity
among generally healthy individuals at risk for T2DM
while following a weight neutral diet.
Materials and methods
Study Ethics
The protocol, protocol amendments, informed consent
documents, applicable privacy regulation authorizations,
recruitment materials and written information provided
to the subjects were reviewed and approved by Schul-
man Associates Institutional Review Board (Cincinnati,
OH) before any subject participated in any clinical trial
activities. Subjects underwent the informed consent pro-
cess prior to study procedures being performed, as
documented by their signature on an informed consent
document.
Study Design
This was a randomized, double blind, placebo con-
trolled, parallel group interventional study.
Study Subjects
Inclusion criteria were: generally healthy men and
women, age 30-70 years with a Body Mass Index (BMI)
of 25-40 kg/m2 and a fasting plasma glucose value of
95-140 mg/dl. Subjects were excluded if they were pre-
viously diagnosed as having T2DM, food allergy or sen-
sitivity to study product ingredients, celiac disease,
uncontrolled hypertension, fasting serum triglyceride
>250 mg/dl, untreated hypothyroidism, recent history of
weight loss, were pregnant, breast feeding or at risk of
becoming pregnant, current or recent history of drug,
alcohol or chemical abuse, or if they had used medica-
tions or herbal remedies for weight loss within 3 months
before treatment in this clinical trial.
Study Diets and Test Products
After undergoing the informed consent process, study
participants underwent a 2 week lead-in period where
they were given nutrition instruction to follow a weight-
maintaining Therapeutic Lifestyle Changes (TLC) diet
regimen throughout the trial [21,22] and received a test
dose of 2 consecutive days of placebo raspberry flavored
water (to determine study participant willingness and
ability to tolerate 3 times a day test beverage consump-
tion). Subjects were interviewed, and instructed to com-
plete a 3-day diary between study visits in order to
assess compliance with the weight maintaining TLC
nutritional recommendations.
If study participants remained eligible and willing to
proceed after the lead-in period, they were randomized
in a double-blind fashion to consume placebo (0 g),
lower dose (1 g) or higher dose (2 g) reduced viscosity
BBG extract (Barliv™ barley betafiber, Cargill, Wayzata,
MN) three times daily with meals or food (total daily
dose of BBG: 0 g/d, 3 g/d or 6 g/d) over a 12-week per-
iod. BBG, a soluble fiber, is Generally Regarded as Safe
(GRAS).
Compliance with study product consumption was
evaluated by subject interview, by reviewing the study
product consumption record which subjects were
asked to complete each day and by counting the used
and unused study product containers which were
returned to the research site at scheduled visits. Proto-
col non-compliance was defined as consumption of
<75% or >125% of the scheduled intakes of the study
beverage.
Raspberry flavored beverages with a pH of 3.2 were
thermally processed and aseptically packaged into 11
fluid ounce packages. All beverages were lightly swee-
tened using a combination of 2% sucrose and sucra-
lose, yielding 6.6 grams of sugar per serving of each
treatment beverage. Incremental addition of BBG
extract to achieve the low and high doses of BBG
resulted in 35 and 38 calories per serving, respectively,
compared to 32 calories for the placebo (Table 1).
BBG content of the beverages was verified after pro-
duction by Covance Laboratories (Madison, WI) using
the American Association of Analytical Chemists
method 995.16. No change in BBG content was
observed with subsequent analysis after completion of
the study.
Table 1 Nutrient Content of Flavored Beverages per
Individual Serving (11 fl oz)
Amount per Serving Placebo Low Dose (1
g)
High Dose (2
g)
Calories (kcal) 32 35 38
Total Fat (g) 0 0 0
Total Carbohydrates
(g)
7.3 8.7 10.0
Sugars (g) 6.6 6.6 6.6
B-Glucan (g) 0 1 2
Protein (g) 0 0 0
Bays et al. Nutrition & Metabolism 2011, 8:58
http://www.nutritionandmetabolism.com/content/8/1/58
Page 2 of 10
Study Visits and Measurements
Six study visits occurred over 14 weeks and fasting
blood work was drawn at visits 1, 2, 4, 5 and 6 on
weeks -2, 0, 6, 9 and 12. Study visit procedures included
a physical exam during visits 2 (randomization) and 6
(end-of-study) which incorporated vital signs and a
pregnancy test. Subjects were counseled in the weight-
maintaining TLC diet regimen and encouraged to main-
tain their baseline weight for the 12-week duration of
the study. Subjects completed 3-day diet diaries in order
to assess compliance with the background diet. BMI was
calculated by dividing weight in kilograms (kg) by height
in meters (m) squared and reported as kg/m2. Fasting
blood was drawn for chemistry, plasma glucose and
insulin, and homeostasis model assessment of insulin
resistance (HOMA-IR) values [23] and Matsuda Index
[24,25]. HOMA-IR is a measure of insulin “resistance”
(mainly in the liver) and the Matsuda Index is a mea-
sure of insulin “sensitivity” (mainly in the muscle). A 75
g glucose drink was administered for the OGTT with
subsequent blood draws for measurement of glucose
and insulin at 30, 60, 90 and 120 minutes (+/- 5 min-
utes) after the time of dosing at the second (randomiza-
tion) and last visits only. A central laboratory (Quest
Laboratory, Lexington, KY) was used for laboratory test-
ing and safety was evaluated by reviewing all treatment-
emergent adverse events (AE) and any abnormal labora-
tory values.
Statistical Methods
The primary endpoint measures were fasting and post-
Oral Glucose Tolerance Testing (OGTT) plasma glucose
and insulin. Measures at week 0 (baseline/randomiza-
tion), week 12 (end of study) and the change from week
0 to week 12 were compared between the three groups
(0, 3 and 6 g/d BBG). The assumptions of normality
were tested using the Shaipro-Wilks test as well as Box-
Cox and logarithmic transformation of the outcome
variable. If no suitable transformation was found, non-
parametric models were used by ranking (r) the mea-
sures first before running the statistical model. Charac-
teristics were compared between treatment groups and
differences in responses between treatment groups were
analyzed by analysis of variance (ANOVA) or Fisher
exact tests as appropriate. The ANOVA statistical mod-
els were used to assess the impact of the terms for treat-
ment, site and treatment by site interactions which were
reduced in a stepwise manner until only significant (p ≤
0.05) terms or treatment group effects remained. Pair-
wise comparisons utilizing Dunnett’s procedure were
made in order to identify if the active groups differed
from the control group. The paired t-test was utilized
for within treatment group comparisons. An incremen-
tal Area Under the Curve (iAUC) analysis analyzed the
timed OGTT data and to compare the values between
groups for the change in iAUC for glucose and insulin
from baseline to end of study after 12 weeks of treat-
ment. Adverse events were tabulated by first occurrence
for each coded term and by body system. Possible differ-
ences in the occurrence of adverse events were assessed
by Chi-square tests, and if statistically significant (p ≤
0.05), then Fisher’s exact test (two-tailed) was utilized
for pair-wise comparisons between each active group
and control. Comparisons between treatment groups for
changes in serum chemistry, hematology and urinalysis
from week 0 to week 12 were assessed by ANOVA with
treatment group as factor.
Results
Subject Population
One hundred fifty nine (159) subjects meeting eligibility
criteria were consented, enrolled and screened; 50 were
randomized (placebo = 17; 3 g/d BBG = 16; 6 g/d BBG
= 17), with 44 subjects completing the 12 week study
(Figure 1). Baseline demographics were comparable
among study groups (Table 2). Study participants were
mostly women (68%) with an average age of 56 years,
BMI 32 kg/m2, and predominantly white (88%). Twelve
percent were African American. Study subjects were
classified according to the American Diabetes Associa-
tion categories for fasting glucose and 2 hr post OGTT
at baseline (Table 3) [3]. Study compliance defined as
compliance with beverage consumption for the 12 week
study included 97.6%, 99.4% and 97.4% of subjects for
the 3 g/d, 6 g/d and placebo respectively. Three subjects
in the placebo group and two subjects in the 6 g/d BBG
group discontinued the study prior to a post-baseline
collection of glucose and insulin; therefore, 14 subjects
in the placebo and 15 subjects in the 6 g/d BBG group
were analyzed at Week 12. In addition, one subject in
the 3 g/d BBG group was missing the week 12 insulin
measure; therefore, 15 subjects in the 3 g/d BBG group
were analyzed at Week 12.
Weight Maintenance and Baseline Values
Subjects maintained their weight during the trial with
no significant weight loss and no significant weight dif-
ferences between treatment groups. At baseline subjects
mean body weight was 90.5, 91.0 and 90.8 kg with a 12
week mean change of 0.7, -0.3 and 0.2 kg for the 3 g/d,
6 g/d and placebo groups respectively (p = 0.475). No
significant differences were found between the groups
for baseline fasting glucose, insulin, or HOMA-IR levels
(Table 4).
Fasting Plasma Glucose
Mean baseline fasting plasma glucose values were simi-
lar in the three groups with values ranging between 99.1
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mg/dl to 103.7 mg/dl (Table 4). Although not statisti-
cally significant, over the 12 weeks of the trial, the mean
fasting glucose levels increased in all groups, but
numerically less so in the 6 g/d BBG group (7.6, 8.3 and
1.5 mg/dl for the placebo, 3 g/d BBG and 6 g/d BBG
groups respectively).
Fasting Plasma Insulin, HOMA-IR and Matsuda Index
Baseline fasting plasma insulin values were similar in the
three groups with mean values ranging between 6.5 and
8.7 uIU/ml (Table 4). The group receiving 6 g/d BBG
for 12 weeks had significantly reduced fasting serum
insulin values by a mean of 7.8%; decreasing from a
mean of 8.3 to 6.7 uIU/mL compared to placebo which
increased from a mean of 6.5 to 8.6 uIU/mL (p =
0.008). Similarly, 6 g/d of BBG significantly reduced
HOMA-IR from week 0 to week 12 from a mean of 2.1
to a mean of 1.7 compared to placebo which increased
from a mean of 1.7 to a mean of 2.4 (p = 0.014). The
Matsuda Index, which is inversely related to the
HOMA-IR, [24,25] showed a mean decrease of 3.3% for
the 3 g/d and a mean increase of 18.1% for the 6 g/d
BBG compared to the placebo which decreased a mean
of 13.4% (p = 0.129).
Post- OGTT Plasma Glucose and Insulin
Subjects receiving 3 g/d BBG for 12 weeks experienced
a mean 10.2% reduction in glucose iAUC during the
OGTT (-1876 min* mg/dl) compared to subjects receiv-
ing placebo who experienced a mean 7.5% increase
(1234 min* mg/dl) (p = 0.011). The 6 g/d BBG group
showed a similar trend (mean = -76 min* mg/dl), but
was not statistically significant (p = 0.373) (Figures 2
Assessed for eligibility (n=159)
Excluded (n=109)
Not meeting inclusion criteria (n=105)
Declined to participate (n=3)
Other reasons (n=1, enrolment closed)
Available for analysis (n=15)
Withdrawn (n=1)
Missing End of Study measures 
Allocated to 3g/d BBG (n=16)
Withdrawn (n=3)
Began weight loss 
Withdrew consent 
Hx of Muscular Dystrophy
Allocated to 6g/d BBG (n=17) 
Available for analysis (n=15)
Allocation
Analysis
Follow-Up
Enrollment
Allocated to PLACEBO (n=17)
Withdrawn (n=2)
Lost to follow-up 
Began new lipid treatment
Available for analysis (n=14)
Randomized (n=50)
Figure 1 Subject Disposition Chart.
Table 2 Baseline Demographics1,2
Placebo 3 g/d
BBG
6 g/d
BBG
Parameter N = 17 N = 16 N = 17
Female Sex 10 (58.8%)
3
11 (68.8%) 13 (76.5%)
White Race 15 (88.2%) 14 (87.5%) 15 (88.2%)
Age (years) 55.6 (5.2) 55.9 (7.8) 57.1 (6.0)
Body Weight (kg) 93.5 (14.1) 90.9 (12.5) 90.1 (14.1)
Height (cm) 167.9
(10.5)
169.3 (9.4) 168.4
(11.1)
BMI (kg/m2) 33.2 (4.1) 31.8 (4.1) 31.8 (4.6)
Waist Circumference (cm) 109.2 (9.8) 105.4
(11.3)
105.2
(11.2)
Systolic Blood Pressure (mm
Hg)
123.9
(12.6)
123.3
(13.8)
120.9
(10.3)
Diastolic Blood Pressure (mm
Hg)
77.8 (5.2) 78.6 (8.3) 77.4 (6.5)
Heart Rate (bpm) 71.2 (9.0) 64.8 (7.4) 68.1 (7.9)
1 P-values for continuous variables were generated by analysis of variance
with treatment as factor; P-values for categorical variables were derived by
the chi-square test; none were significant (less than 0.05); kcal = kilocalories;
kg = kilogram; cm = centimeter; m = meter, mmHg = millimeters of mercury;
bpm = beats per minute
2 Data represented includes all randomized subjects
3Sex and Race values are presented in this table as N (%) while all other
values are presented as Mean (Standard Deviation)
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and 3). Mean insulin iAUC changes from week 0 to
week 12 were 134, 739 and -59 min* uIU/mL for the
placebo, 3 g/d and 6 g/d respectively (not significant)
(Figures 4 and 5).
Adverse Events
A total of 69 adverse events were reported including 17
in the placebo group (7 subjects), 18 with 3 g/s BBG (7
subjects) and 34 with 6 g/d BBG (10 subjects) (p =
0.540). The most common adverse events included diar-
rhea, abdominal distension and flatulence. These adverse
events were typically mild and self-limited, with no sig-
nificant differences between the study groups. No
reported serious adverse events occurred during this
trial and no subjects withdrew from this study due to an
adverse event.
Discussion
In this study, 6 g/d of reduced viscosity BBG consumption
over 12 weeks improved insulin sensitivity (i.e. reduced
fasting insulin and HOMA-IR) in generally healthy study
subjects with baseline hyperglycemia, but without a prior
Table 3 American Diabetes Association (ADA) Classification at Baseline1
Parameter ADA
Classification
Placebo
(N = 17)
3 g/d BBG
(N = 16)
6 g/d BBG
(N = 17)
p-
value2
Fasting Plasma Glucose (mg/
dL)
Normal: Fasting Plasma Glucose < = 99 mg/dL 9; 95.1 (1.3) 6; 91.7 (2.9) 7; 91.0 (2.5) 0.335
Impaired: Fasting Plasma Glucose 100- 125 mg/dL 8; 110.3
(2.4)
9; 108.2 (2.1) 10; 105.6
(1.0)
0.218
Diabetes Mellitus: Fasting Plasma Glucose >= 126 mg/
dL
1; 145.0
OGTT (mg/dL): 2 hrs post dose Normal: Glucose at 2 hours < = 139 mg/dL 9; 94.6 (7.7) 11; 101.3
(8.0)
13; 103.5
(6.8)
0.699
Impaired: Glucose at 2 hours 140-199 mg/dL 5; 169.6
(8.1)
3; 176.3
(13.9)
3; 160.3 (3.7) 0.568
Diabetes Mellitus: Glucose at 2 hours >= 200 mg/dL 3; 212.0
(5.0)
2; 229.5 (2.5) 1; 201.0 0.093
Values presented are N; Mean (Standard Error of Mean)
1 Data represented includes all randomized subjects
2 P-values generated for each group by ANOVA with treatment group as factor.
Table 4 Fasting Glucose, Insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)1
Parameter Visit Placebo
N = 14
3 g/d BBG
N = 15
6 g/d BBG
N = 15
p-value2 Pairwise
Comparisons3
Fasting Plasma Glucose (mg/dL) Week 0 102.4 (2.4) 103.7 (3.9) 99.1 (2.3) 0.775 (r) 3 g/d: 0.977;
6 g/d: 0.833
Week 12 110.1 (4.4) 112.0 (7.6) 100.6 (3.1)
Change 7.6 (4.7) 8.3 (7.3) 1.5 (3.0) 0.399 (r) 3 g/d: 0.577;
6 g/d: 0.305
Fasting Insulin (uIU/mL) Week 0 6.5 (1.1) 8.7 (1.6) 8.3 (1.6) 0.752 (r) 3 g/d: 0.671;
6 g/d: 0.856
Week 12 8.6 (1.8) 8.3(1.6) 6.7 (1.3)
Change 2.1 (1.2) -0.4 (.8) -1.6 (1.0) 0.014 (r) 3 g/d: 0.091;
6 g/d: 0.008
HOMA-IR Week 0 1.7 (0.3) 2.3 (0.5) 2.1 (0.4) 0.834 (r) 3 g/d: 0.771;
6 g/d: 0.952
Week 12 2.4 (0.5) 2.3 (0.5) 1.7 (0.3)
Change 0.7 (0.3) -0.0 (0.3) -0.4 (0.3) 0.025 (r) 3 g/d: 0.130;
6 g/d: 0.014
Matsuda Index Week 0 16.0 (2.6) 18.1 (4.1) 16.7 (3.8)
Week 12 14.1 (3.4) 17.4 (4.7) 17.5 (3.7)
%
Change
-13.4 (9.4) -3.3 (10.9) 18.1 (12.2) 0.928 (r) 3 g/d: 0.901;
6 g/d: 0.949
Values presented are Mean (Standard Error of Mean); Change = Change from Week 0 to 12
1 Data represented includes only subjects with end of study values
2P-values generated from final analysis of variance model; (r) indicates values were ranked prior to analysis.
3Pairwise comparisons to Placebo derived by Dunnett’s procedure
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diagnosis of diabetes mellitus. The fasting plasma glucose
levels had less of a numeric rise among the group receiv-
ing 12 weeks of 6 g/d BBG compared to the placebo group
(not significant). Because this trial was designed to ensure
study subjects underwent protocol-directed maintenance
of body weight, it is noteworthy that the metabolic find-
ings occurred without significant weight changes in any of
the study groups.
Acute, single-meal studies or observations for less that
24-hours, have documented that acute ingestion of BBG
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Figure 2 Post Oral Glucose Tolerance Testing (OGTT) Plasma Glucose: Baseline (Mean +/- SEM).
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Figure 3 Post Oral Glucose Tolerance Testing (OGTT) Plasma Glucose: Week 12 (Mean +/- SEM).
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is associated with significant decreases in postprandial
glycemia and insulinemia [16-20,26-37]. Four short-term
clinical trials of 4 to 6 week duration have not docu-
mented changes in fasting blood glucose and insulin
values comparing BBG consumption to control foods or
products [38-41]. Generally, these studies were of sub-
optimal duration and most were not powered to detect
the small changes that might be expected in non-dia-
betic subjects; however, one study [38] found a signifi-
cant reduction in postprandial blood glucose iAUC
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Figure 4 Post Oral Glucose Tolerance Testing (OGTT) Insulin: Baseline (Mean +/- SEM).
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values after four weeks of treatment in the six subjects
in that cross over study. One, longer-term, cross over
study with a 12-week treatment duration found post-
prandial insulin values were significantly increased while
the favorable reductions in fasting plasma glucose
(-7.3%), fasting plasma insulin (-5.9%) and post-prandial
glucose values (-20%) were not statistically significant
for the eleven T2DM male subjects in this trial [42].
Consistent with prior studies [10-20,26-38,42], this
study showed similar improvements in some but not all
measured parameters of glucose homeostasis. Of inter-
est, prior trials inconsistently suggested dietary fiber
consumption may increase satiety and decrease caloric
intake [32-36]. If a reduction in body weight were
allowed through utilizing a different study design than
this study, and if weight loss were achieved, then it
might be argued that any improvement in measures of
glucose metabolism were simply due to a reduction in
body weight. However, since this study demonstrated
BBG improved glycemic parameters despite no change
in body weight, this suggests BBG in humans may have
glycemic benefits beyond weight loss, as found with
soluble fibers studied in animals [43,44].
Although the data are not always consistent, the
degree by which soluble fibers favorably affect metabolic
parameters (fasting glucose or insulin, postprandial glu-
cose or insulin) may be somewhat dependent upon the
viscosity [40-42]. Like other viscous soluble fibers, BBG
ingestion reduces postprandial glycemia and insulinemia
[15]. Possible mechanisms describing how viscous solu-
ble fibers may improve glucose metabolism and insulin
sensitivity include slow absorption of glucose in the
small intestine, colonic fermentation, and potential
effects upon gastrointestinal hormones [9]. Colon fer-
mentation after consuming a meal containing indigesti-
ble carbohydrates (like barley beta-glucan) may
contribute to subsequent meal improvements in post-
prandial glycemia [45]. Increased serum short chain
fatty acid concentrations resulting from colonic fermen-
tation of soluble fibers may have favorable effects on
hepatic lipid metabolism and improve glucose metabo-
lism [46,47].
Limitations of this study relate to the relatively
small sample size. The findings support potential con-
firmatory trials with this same product formulation
and related formulations of this product. Another
limitation is that while this trial was longer than
many previous trials with this agent, even longer trials
may provide more information regarding the clinical
implications regarding the onset of type 2 diabetes
mellitus. Future studies might evaluate both longer
terms of treatment (perhaps a year or more in combi-
nation with weight loss programs for those who are
overweight and balanced diet counseling for all) as
well as additional blood sampling times after treat-
ment since the pharmacodynamic effects of BBG may
last longer than the initial 2 hours sampled in this
trial.
From a safety and tolerability perspective, the flavored
water beverage containing BBG was generally well toler-
ated, with no serious adverse experiences and no signifi-
cant differences between groups for adverse events.
Conclusions
In summary, this study supports that the 6 g/d BBG
beverage consumed over 12 weeks improves insulin sen-
sitivity among hyperglycemic individuals who have no
prior diagnosis of diabetes mellitus and no change in
body weight. This study suggests BBG may slow the
deterioration of insulin sensitivity for individuals at
increased risk for diabetes mellitus.
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